González-Figueroa M, Canales-Muñoz JL, Aguayo-Alcaraz G, Zamora-Vázquez G

Language: Spanish
References: 23
Page: 199-204
PDF size: 42.10 Kb.

ABSTRACT

Objective: to determine the cost of health care in hemophilic children
Methods: a study of costs analysis of children under 16 years with haemophilia type A and B with different severity grade in one year period was performed. Sociodemographic and clinical data were included. The costs of: 1) ambulatory care, 2) use of emergency services, 3) hospital stay, 4) drugs, 5) antihaemophilic treatment, 6) laboratory and 7) image studies were estimated. We obtained costs for each patient during a year with micro costs technique.
Results: we found 52 children (92.3 % with haemophilia type A). Mean Age was 9.1 years. A half of them started treatment at the age of one year old, with 7.4 years of following. They had 6.7 average visits per year and 13 emergency hospitalization; haemartrosis was the main cause of hospitalization. Five children had more than 40 hospitalization and 27 cases with 1.9 hospitalization. The hospital average stay was 7.4 days. Total annual cost was 116 000 pesos. Higher cost was for the anti hemophilic factor with 73 052 pesos.
Conclusions: the cost was similar to others Latin American studies and lower than in developed countries, however, factor replacement therapy accounts for most of the costs.

REFERENCES

1. Di Paola J, Goldman T, Qian Q, Patil SR, Schutte BC. Breakpoint of a balanced traslocation (X:14) (q27.1;q32.3) in a girl with severe haemophilia B maps proximal to the factor IX gene. J Thromb Haemost 2004;2(3):437-440.

2. Lee C, Sabin C, Miners A. High cost, low volume care: the case of haemophilia. BJM 1997;315 (7114):962-963.

3. Santiago-Borrero PJ, Ortiz Rivera-Caragol E, Maldonado NI. Finnacial aspects of haemophilia care in Puerto Rico and other Latin American countries. Haemophilia 1999;5(6):386-391.

4. Di Paola J, Nugent D, Young G. Current therapy for rare factor deficiencies. Haemophilia 2001;7 (Suppl 1):16-22.

5. Knight C. Health economics of treating haemophilia A with inhibitors. Haemophilia 2005;11(Suppl 1):11- 7.

6. Srivastava A, You SK, Ayob Y, Chuansumrit A, de Bosch N, Pérez-Bianco Ala F. Hemophilia treatment in developing countries: products and protocols. Semin Thromb Hemost 2005;31(5):495-500.

7. Fischer K, Van den Berg HM, Thomas R, Kumar S, Poonnoose P, Viswabandya A, et al. Dose and outcome of care in haemophilia–how do we define cost-effectiveness? Haemophilia 2004;10(Suppl 4): 216-220.

8. DiMichele D, Chuansumrit A, London AJ, Thompson AR, Cooper CG, Killian RM, et al. Ethical issues in haemophilia. Haemophilia 2006;12(Suppl 3):30- 35.

9. Aledort LM. Economics of hemophilia care. Haemostasis 2000;30(6):333-336.

10. Auerswald G, von Depka Prondzinski M, Ehlken B, Kreuz W, Kurnik K, Lenk H, Scharrer I, et al. Treatment patterns and cost-of-illness of severe haemophilia in patients with inhibitors in Germany. Haemophilia 2004;10(5):499-508.

11. Gautier P, D’Alche-Gautier MJ, Coatmelec B, Marques- Verdier A, Bertrand MA, Dieval J, et al. Cost related to replacement therapy during hospitalization in haemophiliacs with or without inhibitors: experience of six French haemophilia centres. Haemophilia 2002;8(5):674-679.

12. Mannucci PM. The choice of plasma-derived clotting factor concentrates. Baillieres Clin Haematol 1996;9(2):273-290.

13. Teitel J. Inhibitor economics. Semin Hematol 2006; 43(2 Suppl 4):S14-S17.

14. Carcao M, Ungar WJ, Feldman BM. Cost-utility analysis in evaluating prophylaxis in haemophilia. Haemophilia 2004;10(Suppl 1):50-57.

15. Lippert B, Berger K, Berntorp E, Giangrande P, van den Berg M, Schramm W; European Haemophilia Economic Study Group. Cost effectiveness of haemophilia treatment: a cross-national assessment. Blood Coagul Fibrinolysis 2005;16(7):477-485.

16. Harper P, Brasser M, Moore L, Teague L, Pitcher L, Ockelford P. The challenge arising from the cost of haemophilia care: an audit of haemophilia treatment at Auckland Hospital. N Z Med J 2003;116 (1180):U561.

17. Steen Carlsson K, Hojgard S, Lethagen S, Berntorp E, Lindgren B. Economic evaluation: what are we looking for and how do we get there? Haemophilia 2004;10(Suppl 1):44-49.

18. Putnam KG, Bohn RL, Ewenstein BM, Winkelmayer WC, Avorn J. A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and hightitre inhibitors. Haemophilia 2005;11(3):261-269.

19. Globe DR, Curtis RG, Koerper MA; HUGS Steering Committee. Utilization of care in haemophilia: a resource-based method for cost analysis from the Haemophilia Utilization Group Study (HUGS). Haemophilia 2004;10(Suppl 1):63-70.

20. Joshi AV, Stephns JM, Munro V, Mathew P, Botteman MF. Pharmacoeconomic analysis of recombinant factor VIIa versus APCC in the treatment of minor-to-moderate bleeds in hemophilia patients with inhibitors. Curr Med Res Opin 2006; 22(1):23-31.

21. Heemstra HE, Zwann T, Hemels M, Feldman BM, Blanchete V, Kern M, et al. Cost of severe haemophilia in Toronto. Haemophilia 2005;11(3):254-60.

22. Ross-Degnan D, Soumerai SB, Avorn J, Bohn RL, Bright R, Aledort LM. Hemophilia home treatment. Economic analysis and implications for health policy. Int J Technol Assess Health Care 1995;11(2): 327-344.

23. Martínez-Murillo C, Quintana S, Ambríz R, Benítez H, Bergest A, Collazo J, et al; Comité Mexicano de Hemostasia y Trombosis. Economic model of hemophilia in Mexico research team. An economic model of hemophilia in Mexico. Haemophilia 2004; 10(1):9-17.